Abstract
The change of Intellectual Property Protection (IPP) from a softer process patenting to a stronger product patenting in Indian Pharmaceutical Industry (IPI) is attracting many global drug majors to source their production from India, which is the fourth largest producer of pharmaceuticals in the world. In this paper, the interests of different stake holders like the buyers (multinational enterprises), who are searching for efficient partners and the vendors (Indian drug producers) that are competing for the contracts, are analysed for a suitable efficiency evaluation criterion. The primary objective of this paper is to study how various firms in the IPI with different business strategies, competing for the same opportunities can find suitable benchmarking peer groups to meet the challenges of a dynamic business environment using data envelopment analysis (DEA). A multiple objective DEA model that determines suitable peer groups for inefficient companies is discussed along with more traditional DEA models. The proposed model has the flexibility to include inputs like R&D expenditure and outputs like Exports that are not homogeneously distributed across the firms and address the interests of various stake holders like buyers and vendors simultaneously.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.